No abstract available
Keywords:
ADA, adalimumab; COVID-19, coronavirus disease 2019; DMASD, disease-modifying antisarcoid drug; GC, glucocorticoid; SARS; coronavirus disease; diffuse lung disease; immunosuppressives; sarcoidosis; severe acute respiratory syndrome.
MeSH terms
-
Betacoronavirus*
-
COVID-19
-
Coronavirus Infections / complications*
-
Coronavirus Infections / epidemiology
-
Disease Management*
-
Humans
-
Pandemics*
-
Pneumonia, Viral / complications*
-
Pneumonia, Viral / epidemiology
-
SARS-CoV-2
-
Sarcoidosis / complications
-
Sarcoidosis / therapy*